Update (June 21, 2026): Systematic Review Maps Fluralaner's Efficacy — and Its Limits as a Non-Repellent

TL;DR

A 2025 PRISMA systematic review of fluralaner across 121 studies found broad acaricidal efficacy but important limits — it does not prevent bites or blood-borne pathogen transfer, and most safety data come from small, fair-quality studies.

What just dropped

• Jiang and Old (2025, PeerJ, https://europepmc.org/article/MED/40093406) screened 250 references and analyzed 121 peer-reviewed articles using PRISMA, the Cochrane risk-of-bias tool, and study-quality and size ranking.
• Fluralaner efficacy had been assessed across 14 mammalian species and pharmacokinetics in 15; it was mostly effective against ectoparasites when re-infection was unlikely.
• Critically, fluralaner did not prevent bites from blood-sucking ectoparasites and could not prevent blood-borne pathogen transfer to host animals.
• The drug was deemed moderately safe, but most studies were of fair quality and based on small or very small samples, and extended fecal detection raised environmental-contamination concerns.

Context

These findings matter for expectation-setting: an acaricide that kills mites and ticks after attachment is not the same as a repellent, so vector-borne-disease prevention still depends on the kill-speed and the local pathogen-transmission window. A large owner-reported survey of canine isoxazoline use (Palmieri et al., 2020, Vet Med Sci, https://europepmc.org/article/MED/32485788) provides complementary real-world safety signal-gathering that the authors of controlled trials cannot capture, underscoring why pharmacovigilance remains important alongside registration studies.

What this changes in Fluralaner (Bravecto) for Canine Generalized Demodicosis

The demodicosis evergreen focuses on mite elimination, where fluralaner performs well. This review adds nuance for the broader ectoparasite conversation — emphasizing that efficacy against mites should not be over-extrapolated to vector-borne-disease prevention, and that the safety evidence base, while reassuring, is still limited in quality and size.

References

1. Jiang Y, Old JM. 2025. A systematic review of fluralaner as a treatment for ectoparasitic infections in mammalian species. PeerJ 13:e18882. https://europepmc.org/article/MED/40093406 [via]
2. Palmieri V, Dodds WJ, Morgan J, et al. 2020. Survey of canine use and safety of isoxazoline parasiticides. Vet Med Sci 6(4):933-945. https://europepmc.org/article/MED/32485788

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-21-fluralaner-systematic-review-efficacy-limits

Related reads

• Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
• Sarolaner Canine Generalized Demodicosis